Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(13 sites)

Belgium

Institut Roi Albert II - UC Louvain, Brussels

UZA, Edegem

Universitair Ziekenhuis Gent, Ghent

UZ Leuven, Leuven

France

Institut Bergonie, Bordeaux